Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer

This publication has 10 references indexed in Scilit:

• A Time to Keep and a Time to Cast Away Categories of Tumor Response
  Journal of Clinical Oncology, 2011
• A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
  Annals of Oncology, 2011
• Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
  Cancer Chemotherapy and Pharmacology, 2010
• Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
  Journal of Clinical Oncology, 2009
• Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
  Clinical Pharmacology & Therapeutics, 2009
• Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
  Journal of Clinical Oncology, 2007
• Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2006
• AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts
  Cancer Research, 2006
• Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent
  Journal of Clinical Oncology, 2006
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000